Zomedica Corp. (ZOMDF)
| Market Cap | 78.40M +0.6% |
| Revenue (ttm) | 36.88M +30.1% |
| Net Income | -18.95M |
| EPS | -0.02 |
| Shares Out | 979.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 246,840 |
| Open | 0.0762 |
| Previous Close | 0.0780 |
| Day's Range | 0.0762 - 0.0800 |
| 52-Week Range | 0.0600 - 0.1580 |
| Beta | 1.37 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 28, 2026 |
About Zomedica
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. It offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. The company provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of p... [Read more]
Financial Performance
In 2025, Zomedica's revenue was $32.03 million, an increase of 17.39% compared to the previous year's $27.29 million. Losses were -$81.86 million, 74.2% more than in 2024.
Financial StatementsNews
Zomedica Announces Strategic Partnership with Veterinary Study Groups (VMG) to Deliver Advanced Veterinary Technologies to Independent Practices
New agreement brings innovative diagnostic, shock wave therapy, and remote monitoring solutions to more than 2,000 member practices across the United States ANN ARBOR, MI / ACCESS Newswire / September...
Zomedica Announces "Fourth Friday at Four" Webinar on September 25, 2026: Inside Zomedica's Marketing Engine: How Demand Becomes Revenue
September session to spotlight how Zomedica's marketing function creates demand, equips the field, and supports utilization across the company's diagnostic and therapeutic portfolios ANN ARBOR, MI / A...
Zomedica Transcript: Investor update
International expansion is driving strong revenue growth, with sales up 37% overall and 17% internationally in Q2 2026. The asset-light distribution model, recurring revenue from consumables, and disciplined cost management are supporting progress toward cash flow breakeven and profitability in 2027.
Zomedica Announces Strategic Collaboration with Boehringer Ingelheim Animal Health Canada Inc. to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) Platform
Collaboration with one of the world's largest animal health companies expected to accelerate TRUFORMA adoption, expand installed base, and drive recurring diagnostic revenue in Canada ANN ARBOR, MI / ...
Zomedica Announces "Fourth Friday at Four" Webinar on August 28, 2026: Zomedica International: Building a Global Platform for Veterinary Innovation
August session to spotlight Zomedica's international expansion strategy, distributor infrastructure, global market opportunity, and the commercial leadership driving growth across five continents ANN ...
Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity
Zomedica surpasses $9 million in second quarter revenue for the first time while extending its record of consecutive year-over-year revenue growth to 22 quarters. ANN ARBOR, MI / ACCESS Newswire / Aug...
Zomedica Quarterly report: Q2 2026
Zomedica has published its Q2 2026 quarterly earnings report on August 5, 2026.
Zomedica Earnings release: Q2 2026
Zomedica released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Zomedica Launches the PulseVet Acoustic Muffler(TM) Accessory for PulseVet(R) Shock Wave System
The accessory reduces sound in the treatment environment while maintaining the trusted efficacy of PulseVet® shock wave therapy ANN ARBOR, MI / ACCESS Newswire / August 4, 2026 / Zomedica Corp. (OTCQB...
Zomedica Transcript: Investor update
Sales strategy centers on a five-pillar framework and a multi-channel, specialized sales force, driving tailored solutions and cross-selling across a growing five-platform portfolio. Revenue reached $31.19 million in 2025, with strong liquidity and continued product launches, while profitability and share buybacks are targeted for 2027.
Zomedica Announces "Fourth Friday at Four" Webinar on July 24, 2026: Zomedica's Sales Organization - From Strategy to the Clinic
July session to spotlight the specialized, coordinated commercial organization that turns product innovation into clinical adoption, sustained utilization, and long-term recurring revenue ANN ARBOR, M...
Zomedica Transcript: Investor update
A disciplined Five Pillars framework drives product innovation, operational efficiency, and recurring revenue growth, with strong adoption in both US and international markets. Management targets cash flow breakeven by Q4 2026 and GAAP profitability in 2027, supported by ongoing cost control, product launches, and expanding partnerships.
Zomedica's Assisi Loop(R) Products Designated "Fear Free(R)" as Alliance to Advance Low Stress Care and Pet Wellbeing Continues with Fear Free, LLC
Collaboration with Fear Free and Zomedica reinforces Assisi Loop tPEMF™ therapy as a low-stress option for pets. ANN ARBOR, MI / ACCESS Newswire / June 25, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedi...
Zomedica Announces "Fourth Friday at Four" Webinar on June 26, 2026: The Five Pillars of Zomedica - Framework for Clinical Value and Shareholder Returns
June session to present the strategic framework behind every Zomedica product and investment decision, connecting pet care outcomes, veterinary practice performance, and long-term recurring revenue gr...
Zomedica Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 35% year-over-year to $8.8 million, driven by strong diagnostics and recurring consumables, with gross margin at 62% and operating expenses down 21%. The company targets cash flow breakeven by end of 2026 and profitability in 2027, supported by new product launches and international expansion.
Zomedica Quarterly report: Q1 2026
Zomedica has published its Q1 2026 quarterly earnings report on May 29, 2026.
Zomedica Earnings release: Q1 2026
Zomedica released its Q1 2026 earnings on May 29, 2026, summarizing the period's financial results.
Zomedica's PulseVet System Repeats as Official Shock Wave of the United States Eventing Association
Collaboration with USEA for Zomedica's PulseVet® shock wave system will increase brand awareness among Eventing enthusiasts. ANN ARBOR, MI / ACCESS Newswire / May 20, 2026 / Zomedica Corp. (OTCQB:ZOMD...
Zomedica Announces "Fifth Friday at Four" Webinar on May 29th: First Quarter 2026 Financial Results and a Deep Dive into the Companion Animal VetTech Market
May session to review Q1 2026 financial results alongside an investor-focused look at the companion animal market for veterinary technology and Zomedica's integrated small-animal portfolio, spanning i...
Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity
Zomedica surpasses $8 million in first quarter revenue for the first time and delivers record year-over-year revenue for 21st straight quarter. ANN ARBOR, MI / ACCESS Newswire / May 6, 2026 / Zomedica...
Zomedica Proxy statement: Proxy filing
Zomedica filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Zomedica Proxy statement: Proxy filing
Zomedica filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Zomedica Announces “Fourth Friday at Four” Webinar on April 24th: A Behind-the-Scenes Look at Manufacturing Excellence and Operational Scale
April session to take investors inside Zomedica's manufacturing operations - showcasing quality systems, automation, and teams driving scalable product fulfillment providing substantial margins ANN AR...
Zomedica Proxy statement: Proxy filing
Zomedica filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
Zomedica Announces Strategic Collaboration with Boehringer Ingelheim to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) Platform
Collaboration with one of the world's largest animal health companies expected to accelerate TRUFORMA adoption, expand installed base, and drive recurring diagnostic revenue ANN ARBOR, MI / ACCESS New...